Today Bioverativ Inc (NASDAQ:BIVV) Reported Decrease in Shorted Shares

March 31, 2018 - By Richard Conner

The stock of Bioverativ Inc (NASDAQ:BIVV) registered a decrease of 76.05% in short interest. BIVV’s total short interest was 2.30M shares in March as published by FINRA. Its down 76.05% from 9.60 million shares, reported previously. With 5.19M shares average volume, it will take short sellers 0 days to cover their BIVV’s short positions. The short interest to Bioverativ Inc’s float is 2.13%.

The stock increased 0.32% or $0.33 during the last trading session, reaching $104.98. About 792,967 shares traded. Bioverativ Inc. (NASDAQ:BIVV) has 0.00% since March 31, 2017 and is . It has underperformed by 11.55% the S&P500.

Bioverativ Inc., a biotechnology company, focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the United States and Japan. The company has market cap of $11.36 billion. The firm offers ELOCTATE, an antihemophilic factor Fc fusion protein; and ALPROLIX, a coagulation factor IX (Recombinant) Fc fusion protein for the treatment of hemophilia A and B. It has a 32.01 P/E ratio. It is also developing BIVV 001 (rFVIIIFc-VWF-XTEN), a preclinical program of the combination of factor VIII-Fc fusion protein for the treatment of hemophilia A; BIVV 002 (rFIXFc-XTEN), a preclinical program for a recombinant factor IX replacement product for the treatment of patients with hemophilia B; and Bi-Specific antibody program, a preclinical program to develop a non-factor bi-specific antibody for the treatment of patients with hemophilia A.

Bioverativ Inc. (NASDAQ:BIVV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: